QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.104.001354v1 33/2/219    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zimmermann, C. Articles by Drewe, J. Search for Related Content PubMed PubMed Citation Articles by Zimmermann, C. Articles by Drewe, J.

MAPPING OF MULTIDRUG RESISTANCE GENE 1 AND MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN ISOFORM 1 TO 5 mRNA EXPRESSION ALONG THE HUMAN INTESTINAL TRACT

Clinic for Pharmacology and Toxicology (C.Z., H.G., P.H., J.D.), and Department of Gastroenterology and Department of Research (P.H., J.-P.G., C.B.), University Clinic Basel/Universitätsspital Basel, Basel, Switzerland

Efflux transporters such as P-glycoprotein and multidrug resistance-associated proteins (MRPs) in the intestinal wall restrict intestinal drug transport. To overcome this limitation for enteral drug absorption, galenical targeting approaches have been proposed for site-specific luminal drug release in segments of the gut, where expression of the respective absorption-limiting transporter is minimal. Therefore, expression of multidrug resistance gene 1 (MDR1) and MRP1-5 was systematically investigated in 10 healthy subjects. Biopsies were taken from different segments of the gastrointestinal tract (from duodenum and terminal ileum, as well as ascending, transverse, descending, and sigmoid colon). Gene expression was investigated by quantitative real-time PCR (TaqMan). MRP3 appeared to be the most abundantly expressed transporter in investigated parts of the human intestine, except for the terminal ileum, where MDR1 showed the highest expression. The ranking of transporter gene expression in the duodenum was MRP3 >> MDR1 > MRP2 > MRP5 > MRP4 > MRP1. In the terminal ileum, the ranking order was as follows: MDR1 > MRP3 >> MRP1 MRP5 MRP4 > MRP2. In all segments of the colon (ascending, transverse, descending, and sigmoid colon), the transporter gene expression showed the following order: MRP3 >> MDR1 > MRP4 MRP5 > MRP1 >> MRP2. We have shown, for the first time, systematic site-specific expression of MDR1 and MRP mRNA along the gastrointestinal tract in humans. All transporters showed alterations in their expression levels from the duodenum to sigmoid colon. The most pronounced changes were observed for MRP2, with high levels in the small intestine and hardly any expression in colonic segments. This knowledge may be useful to develop new targeting strategies for enteral drug delivery.

This article has been cited by other articles:

				H Nevala, T Ylikomi, and H Tahti Evaluation of the selected barrier properties of retinal pigment epithelial cell line ARPE-19 for an in-vitro blood-brain barrier model Human and Experimental Toxicology, October 1, 2008; 27(10): 741 - 749. [Abstract] [PDF]

				C. MacLean, U. Moenning, A. Reichel, and G. Fricker Closing the Gaps: A Full Scan of the Intestinal Expression of P-Glycoprotein, Breast Cancer Resistance Protein, and Multidrug Resistance-Associated Protein 2 in Male and Female Rats Drug Metab. Dispos., July 1, 2008; 36(7): 1249 - 1254. [Abstract] [Full Text] [PDF]

				K. May, K. Westphal, T. Giessmann, D. Wegner, U. Adam, M. M. Lerch, R. Oertel, R. W. Warzok, W. Weitschies, M. Braeter, et al. Disposition and Antimuscarinic Effects of the Urinary Bladder Spasmolytics Propiverine: Influence of Dosage Forms and Circadian-Time Rhythms J. Clin. Pharmacol., May 1, 2008; 48(5): 570 - 579. [Abstract] [Full Text] [PDF]

				A. Collett, R. H. Stephens, M. D. Harwood, M. Humphrey, L. Dallman, J. Bennett, J. Davis, G. L. Carlson, and G. Warhurst Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the {alpha}-Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): The Rational Use of ex Vivo Intestine to Predict in Vivo Absorption Drug Metab. Dispos., January 1, 2008; 36(1): 87 - 94. [Abstract] [Full Text] [PDF]

				C. Hilgendorf, G. Ahlin, A. Seithel, P. Artursson, A.-L. Ungell, and J. Karlsson Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines Drug Metab. Dispos., August 1, 2007; 35(8): 1333 - 1340. [Abstract] [Full Text] [PDF]

				Y. Meier, J. J. Eloranta, J. Darimont, M. G. Ismair, C. Hiller, M. Fried, G. A. Kullak-Ublick, and S. R. Vavricka Regional Distribution of Solute Carrier mRNA Expression Along the Human Intestinal Tract Drug Metab. Dispos., April 1, 2007; 35(4): 590 - 594. [Abstract] [Full Text] [PDF]

				J. Naud, J. Michaud, C. Boisvert, K. Desbiens, F. A. Leblond, A. Mitchell, C. Jones, A. Bonnardeaux, and V. Pichette Down-Regulation of Intestinal Drug Transporters in Chronic Renal Failure in Rats J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 978 - 985. [Abstract] [Full Text] [PDF]

				N. Petri, E. Bergman, P. Forsell, M. Hedeland, U. Bondesson, L. Knutson, and H. Lennernas FIRST-PASS EFFECTS OF VERAPAMIL ON THE INTESTINAL ABSORPTION AND LIVER DISPOSITION OF FEXOFENADINE IN THE PORCINE MODEL Drug Metab. Dispos., July 1, 2006; 34(7): 1182 - 1189. [Abstract] [Full Text] [PDF]

				R. Ohashi, Y. Kamikozawa, M. Sugiura, H. Fukuda, H. Yabuuchi, and I. Tamai EFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATE Drug Metab. Dispos., May 1, 2006; 34(5): 793 - 799. [Abstract] [Full Text] [PDF]